58 – Communication with Regulators in Early Trials (S4E13)

All right, diving in today. And we always pick
really exciting topics. And today is no different.
Ever wonder what it's like talking to the FDA?
We're trying to navigate international guidelines
when you're trying to get a new drug from the
lab to actually helping people. It's definitely
a process, that's for sure. Oh, yeah. And that's
what we're breaking down today, specifically
those super early clinical trials, phase one,
phase two. These can make or break a new medicine,
right? They really can. And how you communicate
with those regulatory bodies, the FDA and the
ICH, during these early phases, it's not just
a box to check. It's a huge part of setting you
up for success or, frankly, for some pretty big
headaches down the road. Headaches, I think,
is putting it mildly. But that's why we're doing
this deep dive. It's all about understanding
the best practices for communicating with regulators,
what kind of questions they're going to have,
and how you adapt on the fly based on their feedback.
So we've got a ton of really interesting material
to work with today. We do. Everything from the
very specific legal frameworks that the FDA operates
under to some more sort of broader perspectives
on drug development as a whole. Excellent. So
let's get right to it. The FDA, the ICH, these
are the big names everyone's heard of, right?
They're essentially the gatekeepers making sure
everything is safe and effective before a drug
can ever reach patients. Absolutely. They're
ultimately responsible for protecting public
health. Now, the FDA here in the US, they operate
under a very specific legal framework, and it
can seem a little daunting at first. We're talking
about acts like the Federal Food, Drug, and Cosmetic
Act. Big name, big implications. But a key part
we need to focus on today is Title 21 of the
Code of Federal Regulations, especially Part
312. Part 312, okay. This is essentially the
rule book for investigational new drug applications.
your IND. It's your formal request to say, hey,
FDA, we want to start testing this new drug in
humans. And trust me, understanding these regulations
inside and out is not optional. It's your first
step to effective communication because it sets
the rules of the game. Got it. So IND, your ticket
to the game. What about the ICH? They're the
international folks, right? Right. The International
Council for Harmonization. They bring together
regulatory authorities from all over the world
trying to make sure the technical guidelines
for drug development are consistent. across the
globe. So it's not just about what the US wants.
It's about a more global standard. Exactly. Their
guidelines may not be legally binding like the
FDA regulations are here, but they carry a lot
of weight. They really influence what regulators
all over the world expect to see. So you got
to pay attention to both. OK. So say I'm a researcher
and I'm heading into these early clinical trials,
phase I and II. What's the big picture? What
information am I trying to gather at this stage?
And what are those regulators going to be zeroing
in on? So phase I and phase II, you're essentially
laying the foundation. You're figuring out, OK,
how does this drug behave in humans? What does
it do to the body? What does the body do to the
drug? That's your pharmacodynamics and your pharmacokinetics.
Right, right. We hear those terms thrown around
a lot. Yeah, so pharmacodynamics, think of it
like this. It's what the drug does to the body.
Like, does it lower blood pressure? Does it kill
cancer cells? That kind of thing. Pharmacokinetics
is... Well, imagine the drug is on a little journey
through the body. Pharmacokinetics is tracking
that journey. How's it getting absorbed? Where's
it going? How's it breaking down? How's it leaving
the body? Okay, so it's like the drug's travel
itinerary, essentially. Pretty much. And phase
I is all about safety. So you're starting to
figure out what's a safe dose range? What are
the side effects? So we're talking, you know,
first time in humans, really careful monitoring.
Small groups of people. Exactly. You're really
dipping your toes in the water. Then you move
on to phase two. And you're starting to look
at efficacy. OK, is this drug actually doing
what we think it should be doing? Does it show
promise in treating the condition we're targeting?
And you're still, of course, keeping a close
eye on safety at those doses. Right, because
a drug might be safe, but just not effective,
or vice versa. That's right. So by the end of
phase two, you and the regulators should have
a pretty good understanding of the drug's potential
benefits and its risks. And that shared understanding,
that's where those crucial conversations with
the agencies really start to take shape. OK,
I get it, laying the groundwork. But here's a
question. Given that the FDA and ICH are all
about safety and making sure things are done
right, it almost feels a little counterintuitive
to actively reach out to them early on. isn't
there a risk of inviting extra scrutiny? That's
a really common concern. It's like, oh, if I
don't talk to them, maybe they won't notice anything.
But honestly, that's the opposite of what you
want. Early and open communication, it's not
about poking the bear. It's about building a
relationship. Think of it like getting to know
your neighbors. If you start off on the right
foot, it's a lot easier to work things out down
the line. So it's more like, hey, we're doing
this cool thing. Come be a part of it from the
start. Exactly. It's about transparency and collaboration.
By engaging early, you can get a much clearer
idea of what those regulatory expectations really
are. And that can save you a ton of time and
headaches later on. Makes sense. Catch those
potential problems before they become full -blown
regulatory roadblocks. For example, I can't tell
you how many times I've seen companies get tripped
up over something as simple as the starting dose
in a phase I trial. Maybe their preclinical data
showed a certain safety margin, but if they don't
clearly explain that to the FDA and justify their
chosen human dose, it can lead to a lot of back
and forth delays, frustration. So it's like,
show your work. Don't just assume they'll get
it. Precisely. Show your work, be transparent,
and build that trust early on. It really does
pay off. OK, so that's the why of proactive communication.
But how do you actually do it effectively? What
are some practical tips for researchers who are
maybe new to this whole dance with the regulators?
Well, first and foremost, clarity is king. Any
communication you have with the FDA or ICH, whether
it's a formal document or just a quick email
response, it needs to be clear, concise, and
give them all the information they need. No jargon,
no burying the lead. Exactly. And a little tip
I always give people, whenever you're sending
a written communication, start with a super brief
summary of the key questions you're addressing.
It shows the reviewers that you respect their
time, helps them focus on the core of what you're
saying. Like a little table of contents almost.
Exactly. Now, beyond clarity, you also need to
stay up to date. The FDA and ICH guidelines,
they're not static, they evolve, so you got to
keep learning. Especially those IND requirements
we talked about earlier, Part 312, that's your
Bible. if you miss something crucial in that
IND application, that's not going to go over
well. Not at all. And remember, you're providing
a ton of detailed information. It's not just,
hey, we have this new drug. It's here's everything
about it, how it's made, what's in it, how cure
it is, all that CMC stuff. Here's our preclinical
data. Here are the studies we've done in animals.
And here's exactly how we plan to study it in
humans. This is like building a really detailed
case file. Absolutely. You want to leave no room
for doubt. And then, of course, you've got your
clinical trial protocols, your detailed plan
for how the study will be run. All of that needs
to be crystal clear. All right, so we've got
our meticulously crafted IND. We've submitted
it. Our phase I trial is underway. And then boom,
we get a list of questions and concerns from
the FDA. What's the best way to handle that?
Don't panic. This is normal. It's part of the
process. The key is to be prepared. Have a dedicated
team ready to jump on those queries quickly and
efficiently. And when you respond, back everything
up with data. So it's not just, well, we think
this or we feel that. No, it's, here's the data
from our preclinical studies. Here's what we're
seeing in the clinical trial so far. Here's the
published literature that supports our approach.
You want to be able to point directly to the
evidence that supports your decisions. Data,
data. That's the name of the game. And you know,
I've seen this firsthand. I had a client once
who was anticipating a tough question from the
FDA about a potential safety signal based on
their early animal studies. So what did they
do? They proactively prepared this really thorough
analysis, even created some visual summarizing
the data. They compared it to existing treatments.
And when the FDA did raise the question, bam,
they were ready. The regulators were really impressed
with how prepared they were. It's like they were
anticipating the next chess move. Exactly. And
it saved them so much time and back and forth.
It really smoothed things over. So be proactive,
be data driven, and you'll be in a much stronger
position. And what if? During this whole back
and forth, the FDA or ICH suggests that you need
to change something about your trial. Maybe they
have concerns about, you know, who you're enrolling,
the dose you're testing, even the endpoints,
what you're measuring as the outcome. How do
you handle that? Well, that's where flexibility
comes in. You have to remember, the FDA and ICH,
they're the experts. They see a lot of data,
a lot of trials. So if they raise a concern,
it's usually for a good reason. They're looking
out for patient safety, for the scientific integrity
of the trial. So you've got to be willing to
adapt. So it's not like my way or the highway?
Not at all. It's a collaboration. Maybe they
suggest narrowing your inclusion criteria to
focus on a specific patient population, or adjusting
the dose, or adding a new endpoint, or even revising
your statistical analysis plan. Those are all
things that can happen. It's like a constant
fine -tuning based on the feedback you're getting.
Exactly. And if you need to make significant
changes, you'll have to submit a formal amendment
to your IND. That gets reviewed and approved.
before you can implement the changes. So it's
a back and forth. It's not just a one and done
submission. Absolutely. It's a dialogue, a partnership.
OK. So we've talked about the why and the how
of communicating with regulators, but our listeners
always love real world examples. Now, I know
the sources we have don't give us like transcripts
of those early conversations, but are there any
related concepts that we can pull in? to illustrate
these points. For sure. I mean, think about it.
Drug development is becoming more and more complex,
right? You've got all these new technologies,
new types of therapies, and that just inherently
demands a lot more planning, a lot more communication
with the agencies to navigate all the complexities.
That's something we see emphasized again and
again in the literature. Like the more complex
the science gets, the more important that clear
communication becomes. Exactly. And another thing,
one of the sources really hammered home the importance
of having really robust bioanalytical methods
for measuring those pharmacokinetic parameters
we talked about earlier. The drugs travel itinerary.
Right, so you have to be able to accurately measure
how the drug is behaving in the body. If your
methods are sloppy, if they're not well documented,
the regulators are going to have a lot of questions
and that's going to slow things down. So solid
science, solid methods, solid documentation,
that's all part of the communication package.
Absolutely, and you know it's also interesting
to see that There can be some differences in
regulatory perspectives between agencies, like
the FDA might have a slightly different take
on something compared to the European Medicines
Agency, the EMA. Right, because drug development
is a global endeavor these days. It is, and that's
why those early conversations are so crucial.
You want to understand those different viewpoints
early on so you can address potential concerns
and maybe even bridge those gaps in your development
strategy. So think globally, communicate proactively.
Exactly. And remember, one of the biggest takeaways
from our sources is that emphasis on CMC information
in your IND, that's the chemistry, manufacturing,
and control, they really scrutinize that stuff.
So any ambiguity there, any missing information,
it's going to lead to questions, it's going to
lead to delays. So be thorough, be clear, leave
no room for interpretation. Right. And speaking
of regulations, you mentioned 21 CFR Part 312
a few times. Are there any other specific regulations
or ICH guidelines that are super relevant to
this early communication process? Part 312, it's
really comprehensive. It lays out everything
the FDA expects to see in your IND. The CMC details,
the pre -clinical data, the proposed clinical
trial protocols. It also tells you how to submit
amendments to your IND and how to report any
safety issues that come up during your trials.
Now, our sources didn't really dive into specific
ICH guidelines that focus just on early communication,
but there are a ton of ICH guidelines that influence
global standards for clinical trials. Right,
because the ICH is all about harmonizing things
internationally. Exactly. And one really important
set of guidelines is ICH Good Clinical Practice,
GCP. That applies to all phases of clinical trials,
but it really sets the bar for ethical and scientific
quality. It tells you how to design, conduct,
record, and report your trials. And following
those GCP principles is essential. It directly
impacts the quality of the data you're communicating
to regulators. So it's not just about what you
say. It's about how you got the data in the first
place. Absolutely. And one other thing, one of
the sources mentioned specific ICH guidelines,
S3A and S3B, that deal with pharmacokinetic and
toxicokinetic studies in animals. So those give
you really specific guidance on the types of
data regulators expect to see early on. OK, so
lots of specific guidelines to keep in mind.
But one final point that I think is really important,
I know you've alluded to this before, it's not
just about bombarding the regulators with information,
right? Oh, yeah. You can definitely overwhelm
them. That's a recipe for disaster. Remember,
they have a ton of applications to review, a
ton of data to sift through, so your goal should
be to make their lives easier, not harder. So
quality over quantity. Absolutely. Think about
it like writing a good paper. You want to be
clear, concise, well organized. You want to get
your point across without burying it in a mountain
of unnecessary detail. So when communicating
with regulators, less is often more. Absolutely.
Focus on the key data, the key interpretations,
present it in a logical way, a well -structured
submission. It's like a breath of fresh air for
those reviewers. Okay, so let's wrap this up.
What are the essential takeaways for our listeners
about this whole idea of proactive communication
with regulatory agencies during those early clinical
trials? I think the core message is this. Proactive
communication, it's not just a box to check.
It's a crucial part of successful drug development.
Understand the regulatory landscape, the FDA's
requirements, the ICH guidelines. Build that
collaborative relationship with the agencies
early on. Be transparent, be clear, be data driven,
and be ready to adapt. And by doing all that,
you're not just navigating the regulations. You're
actually helping to accelerate the development
of those innovative therapies that are going
to ultimately make a difference in people's lives.
And you know, it really gets me thinking, When
you look at the big picture, how much does that
early, proactive, collaborative dialogue with
regulators shape the whole trajectory of a drug
development program? I mean, think about it.
From those first conversations about your IND
all the way through to approval and beyond, that
open communication can really make or break a
drug's success. So it's not just about getting
a drug approved. It's about getting it approved
efficiently, safely. and ultimately making sure
it reaches the patients who need it most. Exactly.
And that's something I think we all need to keep
in mind. It's a shared responsibility. Absolutely.
All right. Well, on that note, thanks for listening
to another episode of the Deep Dive. Catch you
next time. See you then.